全文获取类型
收费全文 | 4919篇 |
免费 | 166篇 |
国内免费 | 78篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 135篇 |
妇产科学 | 17篇 |
基础医学 | 712篇 |
口腔科学 | 15篇 |
临床医学 | 224篇 |
内科学 | 586篇 |
皮肤病学 | 23篇 |
神经病学 | 306篇 |
特种医学 | 71篇 |
外科学 | 79篇 |
综合类 | 339篇 |
预防医学 | 2427篇 |
眼科学 | 7篇 |
药学 | 131篇 |
中国医学 | 13篇 |
肿瘤学 | 70篇 |
出版年
2023年 | 42篇 |
2022年 | 288篇 |
2021年 | 502篇 |
2020年 | 135篇 |
2019年 | 71篇 |
2018年 | 81篇 |
2017年 | 56篇 |
2016年 | 224篇 |
2015年 | 354篇 |
2014年 | 362篇 |
2013年 | 346篇 |
2012年 | 313篇 |
2011年 | 394篇 |
2010年 | 317篇 |
2009年 | 272篇 |
2008年 | 111篇 |
2007年 | 121篇 |
2006年 | 108篇 |
2005年 | 112篇 |
2004年 | 107篇 |
2003年 | 83篇 |
2002年 | 64篇 |
2001年 | 83篇 |
2000年 | 57篇 |
1999年 | 53篇 |
1998年 | 50篇 |
1997年 | 55篇 |
1996年 | 31篇 |
1995年 | 37篇 |
1994年 | 25篇 |
1993年 | 29篇 |
1992年 | 25篇 |
1991年 | 18篇 |
1990年 | 19篇 |
1989年 | 23篇 |
1988年 | 16篇 |
1987年 | 15篇 |
1986年 | 14篇 |
1985年 | 22篇 |
1984年 | 20篇 |
1983年 | 13篇 |
1982年 | 19篇 |
1981年 | 9篇 |
1980年 | 11篇 |
1978年 | 9篇 |
1976年 | 6篇 |
1975年 | 5篇 |
1973年 | 5篇 |
1971年 | 4篇 |
1969年 | 10篇 |
排序方式: 共有5163条查询结果,搜索用时 15 毫秒
1.
Moncef Khairallah Padmamalini Mahendradas Andre Curi Sana Khochtali Emmett T. Cunningham Jr. 《Ocular immunology and inflammation》2019,27(2):219-228
Purpose: To review the systemic and ocular manifestations of specific emergent viral infectious diseases relevant to the ophthalmologist with particular emphasis on anterior uveitisMethods: Review of literature.Results: Arboviral diseases are among the most important emergent and resurgent human infections, occurring mostly in tropical and subtropical zones, but appearing in virtually all regions of the world as a result of climate change, travel, and globalization. Arboviral infections are transmitted to humans by the bite of hematophagous arthropods, mainly mosquitoes. Systemic disease may range from asymptomatic to life-threatening. A wide variety of ocular manifestations, including uveitis, has been reported in association with these emerging viral diseases. Numerous viruses other than arboviruses also have been recently recognized as a potential cause of uveitis.Conclusions: Proper clinical diagnosis of any emerging infectious disease is based on epidemiological data, history, systemic symptoms and signs, and the pattern of ocular involvement. The diagnosis is usually confirmed by detection of virus-specific DNA or antivirus antibodies in serum. 相似文献
2.
《Ticks and Tick》2020,11(6):101540
Powassan virus (POWV) is a tickborne flavivirus discovered in Ontario, Canada in 1958 that causes long-term neurological sequelae in about half the reported cases and death in a little more than 10 % of cases. The incidence of POWV disease is rising in the United States but there is limited understanding of the scope and causes of recent changes in POWV epidemiology. We focus on quantifying the increase in human POWV disease incidence and infection prevalence in the United States. We also examine differences in the frequency of symptomatic cases and asymptomatic or mildly symptomatic cases, as well as limitations in national and state surveillance for POWV infection. We searched SCOPUS for all articles containing original POWV prevalence research, case studies, or literature reviews published in English. Case studies were supplemented by Morbidity and Mortality Weekly Report POWV data from the Centers for Disease Control and Prevention (CDC) and surveillance information from state health department websites. An increase in the number of POWV cases has been reported in the United States over the past 50 yr, and the geographic range of human POWV cases has expanded. The age distribution of symptomatic POWV cases has shifted, with significantly more individuals over 40 yr old being diagnosed after 1998. The emergence of POWV is due in large part to: (i) a change in transmission of POWV from a vector that rarely bites people (Ixodes cookei) to a new vector that often bites people (Ixodes scapularis) and has expanded its geographic range, (ii) enhanced surveillance efforts for arboviruses, and (iii) a greater awareness of POWV infection. 相似文献
3.
背景 呼吸道合胞病毒(RSV)毛细支气管炎易出现反复喘息,且下呼吸道分泌物中半胱氨酸白三烯(CysLTs)水平升高。而孟鲁司特是一种白三烯受体拮抗剂,关于其治疗RSV毛细支气管炎症状的研究相对较少。目的 探讨孟鲁司特改善婴幼儿RSV毛细支气管炎后症状及减轻反复喘息发作的有效性和安全性。方法 2015年6月-2017年6月连续纳入在潍坊市妇幼保健院出院的RSV毛细支气管炎患儿,随机分为治疗组、对照组。Ⅰ期,治疗组:口服孟鲁司特颗粒(4 mg)12周,1次/d;对照组:口服安慰剂12周,1次/d。对两组无症状天数、个人日记评分进行评估。随访9个月(Ⅱ期),观察Ⅰ+Ⅱ期反复喘息人数和医疗资源应用情况等。依据意向性分析(ITT)原则,应用全分析集(FAS)分析数据。结果 共纳入研究对象186例,治疗组92例,对照组94例。治疗组完成Ⅰ期研究的患儿为89例,对照组为90例;治疗组完成Ⅰ+Ⅱ期的患儿为84例,对照组为86例。治疗组平均依从性为97.8%(7 560/7 728),对照组平均依从性为97.4%(7 690/7 896),两组患儿平均依从性比较,差异无统计学意义(χ2=3.16,P=0.07)。在Ⅰ期研究期间,两组无症状天数、日间无症状天数、夜间无症状天数、个人日记评分比较,差异均无统计学意义(P>0.05)。在整个研究过程中(Ⅰ+Ⅱ期),治疗组RSV毛细支气管炎喘息复发人数少于对照组(P<0.05),治疗组喘息患儿出现2次及以上喘息比例低于对照组(χ2=5.14,P=0.02)。Ⅰ+Ⅱ期研究期间治疗组医疗资源应用人数、β-受体激动剂应用人数、糖皮质激素应用人数、住院人数低于对照组(P<0.05)。在事后亚组分析中,治疗组有湿疹史与父母哮喘史的患儿中无症状天数〔(49.7±20.2)、(51.3±20.9)d〕多于对照组〔(36.3±20.4)、(37.8±19.3)d〕(t=2.19,P=0.03;t=2.24,P=0.03)。整个研究过程中没有患儿因不良反应退出研究,两组间胃肠道紊乱、皮疹、转氨酶升高发生率比较,差异均无统计学意义(χ2=0.23,P=0.63;χ2=0.03,P=0.86;χ2=0.15,P=0.69)。结论 口服孟鲁司特(4 mg)12周不能改善RSV毛细支气管炎患儿呼吸道症状,但能降低患儿反复喘息发作次数。口服孟鲁司特(4 mg)有一定效果且安全。 相似文献
4.
5.
Ana Lopez Alonso 《Platelets》2015,26(4):317-323
AbstractWhile the interactions between Gram-positive bacteria and platelets have been well characterized, there is a paucity of data on the interaction between other pathogens and platelets. However, thrombocytopenia is a common feature with many infections especially viral hemorrhagic fever. The little available data on these interactions indicate a similarity with bacteria-platelet interactions with receptors such as FcγRIIa and Toll-Like Receptors (TLR) playing key roles with many pathogens. This review summarizes the known interactions between platelets and pathogens such as viruses, fungi and parasites. 相似文献
6.
Frédéric Janvier Deborah Delaune Thomas Poyot Eric Valade Audrey Mérens Pierre E. Rollin Vincent Foissaud 《Emerging infectious diseases》2016,22(2):292-294
We evaluated RNA stability of Ebola virus in EDTA blood and urine samples collected from infected patients and stored in West Africa’s environmental conditions. In blood, RNA was stable for at least 18 days when initial cycle threshold values were <30, but in urine, RNA degradation occurred more quickly. 相似文献
7.
《Vaccine》2016,34(45):5436-5441
Influenza is a viral infection that affects much of the global population each year. Vaccination remains the most effective tool for preventing the disease. Live attenuated influenza vaccine (LAIV) has been used since the 1950s to protect humans against seasonal influenza. LAIVs developed by the Institute of Experimental Medicine (IEM), Saint Petersburg, Russia, have been successfully used in Russia since 1987.In 2006, the World Health Organization (WHO) announced a Global action plan for influenza vaccines (GAP). WHO, recognizing potential advantages of LAIV over the inactivated influenza vaccine in a pandemic situation, included LAIV in the GAP.BioDiem Ltd., a vaccine development company based in Melbourne, Australia which held the rights for the Russian LAIV, licensed this technology to WHO in 2009. WHO was permitted to grant sub-licenses to vaccine manufacturers in newly industrialized and developing countries to use the Russian LAIV for the development, manufacture, use and sale of pandemic and seasonal LAIVs. To date, WHO has granted sub-licenses to vaccine manufacturers in China (Changchun BCHT Biotechnology Co., Ltd.), India (Serum Institute of India Pvt. Ltd.) and Thailand (Government Pharmaceutical Organization). In parallel, in 2009, IEM signed an agreement with WHO, under which IEM committed to supply pandemic and seasonal candidate vaccine viruses to the sub-licensees.This paper describes the progress made by collaborators from China, India, Russia and Thailand in developing preventive measures, including LAIV against pandemic influenza. 相似文献
8.
9.
《Journal of infection and chemotherapy》2020,26(7):741-744
Although infectious mononucleosis due to Epstein-Barr virus (EBV) is a common disease among young individuals, central nervous system (CNS) complications are rare. In this report, we describe a case of CNS complications caused by EBV in a previously healthy young woman. She presented to our hospital with a 9-day history of headache and sore throat, followed by the development of fever and facial edema 6 days prior to admission. On Day 2 of admission, she was confused (Glasgow Coma Scale score: 10 points) and had fever, muscle weakness in her right arm and leg, stiff neck, and roving eye movement. We detected EBV in a cerebrospinal fluid (CSF) sample using a polymerase chain reaction (PCR) test. The magnetic resonance imaging of her brain revealed dural enhancement and right parietal and temporal lobe lesions. She was treated with acyclovir and high-dose steroid therapy. She responded well to treatment, recovered without neurologic sequelae, and was discharged home on Day 12.Our experience suggests that PCR detection of EBV DNA in CSF may be useful in diagnosing EBV encephalitis and that prognosis may be associated with an area of the brain that is affected and the time from symptom onset to starting treatment. 相似文献
10.
《Journal of thoracic oncology》2021,16(3):381-394
Immune checkpoint inhibitors (ICIs) have transformed the prognosis of cancers previously considered lethal. The spectrum of therapeutic indications is rapidly expanding, including the vast majority of thoracic malignancies. By enhancing the immune responses against cancer, the ICI treatments lead to the development of immune-related adverse events (irAEs) that may affect any organ. Severity varies from mild to fatal clinical manifestations. Neurologic involvement is relatively rare and highly heterogeneous, including central and peripheral nervous system diseases associated with neural-specific autoantibodies or not, central nervous system vasculitis, and granulomatous and demyelinating disorders. Symptoms often manifest within the first four cycles of treatment and can develop regardless of the class of ICI used. An unfavorable outcome is found in up to one-third of patients and is generally associated with the patients’ clinical characteristics (e.g., age, coexistence of systemic adverse events), cancer type (e.g., lung cancer versus other), and specific clinical setting (e.g., ICI treatment in patients with preexisting paraneoplastic neurologic autoimmunity, ICI rechallenge after a first neurologic irAE). Diagnosis should be suspected in patients with new-onset neurologic symptoms while on ICI treatment which are not explained by metastatic disease or other metabolic/infectious disorders. Recommended treatment is based on clinical severity and consists of ICI discontinuation with or without immunosuppressive/immunomodulatory therapy, although alternative approaches are reasonable depending on cancer status (e.g., aggressive immunosuppression without discontinuing ICI in patients with initial cancer response). Early recognition and appropriate treatment of these neurologic irAEs are crucial for improved patient outcomes and therapeutic planning. 相似文献